Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Optimal patient-centered care is often not being delivered to cancer patients, especially to vulnerable populations like those living in underserved rural areas. This body of work will develop and pilot test a multicomponent intervention approach designed to improve the care and outcomes of cancer patients and their support persons (SPs) during and following their therapeutic journey. The intervention will involve the provision of social prescriptions and web-based micro-learning modules, as well as stepwise care based on ongoing monitoring of symptom burden and health. This project uses the strengths of innovative, individually tailored communication strategies and a comprehensive low-cost approach that are likely to support fair and equal patient access to optimal care beyond the funding period. By using a patient-driven approach in an interdisciplinary setting, it is anticipated that the intervention will improve the health outcomes of various patient populations, especially those living in rural areas. To achieve this, a methodologically robust mixed-methods approach and an effectiveness-implementation hybrid design will be employed to move effective strategies towards implementation into clinical practice. A number of standardized patient-reported outcome and experience measures will be used, including quality of life and knowledge of health and care. As a result of this research, an implementation toolbox will be developed that could be used by clinicians working in different healthcare settings and services, both nationally and internationally, to help provide highest quality cancer care.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Diagnoza raka płuca, jelita grubego, nowotworów krwi lub melanoma w ciągu ostatnich 12 miesięcy
- •Oczekiwana długość życia co najmniej 18 miesięcy
- •Umiejętność mówienia i rozumienia po niemiecku do wypełniania ankiet i wywiadów
- •Leczenie w szpitalnym oddziale onkologii
- •Podpisana zgoda na udział w badaniu
- •Dobry stan ogólny umożliwiający uczestnictwo
- •Możliwość wskazania osoby bliskiej do udziału w badaniu
✗ Disqualifies
- •Brak możliwości wyrażenia świadomej zgody na udział
- •Trudności w samodzielnym wypełnianiu ankiet i wywiadów z powodu problemów z mową, słuchem lub rozumieniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 26, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
University Hospital Augsburg
Augsburg, Germany
University Hospital Erlangen
Erlangen, Germany
University Hospital Regensburg
Regensburg, Germany
University Regensburg
Regensburg, Germany
University Hospital Würzburg
Würzburg, Germany
Faculty of Law, Business & Economics, Inst. for Healthcare Management & Health Sciences
Bayreuth, Germany
Charité - University Medicine Berlin
Berlin, Germany
University Hospital Köln
Cologne, Germany
Trial contact
Anne Herrmann, Prof. Dr.
Hansjoerg Baurecht, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/27/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.